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ABSTRACT
Protein arginine methyltransferases (PRMTs) are essential epigenetic players in living cells. The
dysregulation of PRMTs is closely related to many diseases, including cancer. Based on previously
reported PRMT1 inhibitors bearing the diamidine pharmacophore, a combinatorial high throughput
screening strategy led to compound K313, which possesses a biochemical IC50 value of 0.84 µM against
PRMT1.
Histone code is the post-translational modification patterns appear at histone, which regulates
transcription and many other cellular events. H4R3 is one of the important substrates for both PRMT1
and PRMT5. PRMTs are important in establishing histone code. They are also regulated by the histone
code. In this study, we explored the mechanism of how the post-translational modifications on H4 tail
peptide affect the activity of PRMTs.
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CHAPTER 1. Discovery of K313 as a novel diamidine-structured PRMT1 Inhibitor

Abstract
Protein arginine methyltransferases (PRMTs) are essential epigenetic players in
living cells. Dysregulation of PRMTs is closely related to many diseases, including
cancer. Based on previously reported PRMT1 inhibitors bearing the diamidine
pharmacophore, a combinatorial high throughput screening strategy led to compound
K313, which possesses a biochemical IC50 value of 0.84 µM against PRMT1. K313
significantly inhibited cell proliferation and reduced the arginine methylation level of
MEG01 cells (leukemia) and OVCAR3 cells (ovarian cancer).

1.1
1.1.1

INTRODUCTION
Functions and activities of PRMT1
Epigenetics refers to the functionally relevant changes that are heritable without

altering the nucleotide sequence. [1] Epigenetic changes, mainly DNA methylation and
histone modifications, play critical roles in eukaryotic biology. They are intimately
related to various diseases, including cancer. [2] Protein arginine methyltransferases
(PRMTs) regulate chromatin remodeling by depositing of methyl marks [3] on arginine
residues of histones. They have a broad spectrum of non-histone substrates that are
critical to various regulatory pathways. [4] PRMTs transfer the methyl group from Sadenosylmethionine (SAM or AdoMet) and replace a hydrogen atom on the ω-NG of the
arginine of the substrate, generating the methylated arginine. [5] Nine PRMT isoforms
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(PRMT-1, -2, -3, -4, -5, -6, -7, -8 and -9) have been found in mammalian cells, which are
categorized into type I, type II and type III based on their methylarginine products[6].
Type I PRMTs (PRMT-1, -2, -3, -4, -6 and -8) PRMTs are responsible for the formation
of monomethyl arginine (MMA) and asymmetric dimethylarginine (ADMA). Type II
PRMTs (PRMT-5 and -9) catalyze the formation of MMA and symmetric
dimethylarginine (SDMA), whereas Type III enzyme (PRMT7) only produces MMA.
PRMT1 is predominant in type I PRMTs that accounts for 50% of ADMA formation in
mouse embryonic fibroblasts. [7, 8] PRMTs are involved in critical physiological
processes, including cell death, cell cycle progression, and RNA processing. [9] Although
the biological roles of PRMTs are not fully understood, overexpression and dysregulation
of PRMTs are found in cancer, cardiovascular dysfunction and other pathological
conditions. [10] An increasing number of inhibitors are identified to target histone
modifying enzymes, some have been approved by FDA to treat hematological cancer
(e.g. histone deacetylases inhibitors: vorinostat, belinostat and romidepsin) and many
more are in the clinical trials. [11] Small molecule inhibitors of PRMTs are potential
therapeutics targeting PRMT up-regulation in various diseases, including cancer[10, 12,
13]. They are also ideal chemical tools to uncover and elucidate the biological functions
of PRMTs[14, 15].
1.1.2 PRMT1 as a drug-receptor
To date, various PRMT small molecule inhibitors have been identified [16-18],
including a few PRMT1 inhibitors contain one or two amidine groups, such as
stillbamidine [19] and compound 6d [20] (Figure 1.1.1). The amidine moiety mimics the
side-chain guanidino moiety of the arginine in PRMT substrates, which is rigidly planar,
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highly basic and contains two ω-nitrogen atoms. Previously, we screened a focused
library of diamidine compounds and identified furamidine (DB75) (Figure 1.1.1) as a
lead PRMT1-selective inhibitor in this series. [21] The IC50 value of furamidine was 9.4
±1.1 µM against PRMT1, better than stilbamidine (IC50 = 15.2 ±2.3 µM); and the IC50
values were 18-fold, > 40-fold and 30-fold higher against PRMT5, CARM1 and PRMT6,
respectively. Biophysical assay and molecular docking results suggested that furamidine
primarily acted as a substrate-competitive inhibitor. Furamidine also significantly
reduced cell growth and the ADMA level in leukemia cell lines. It was further used as a
chemical probe to study biological functions of PRMT1 in leukemia cells, as a regulator
of alternative RNA splicing via methylation of RBM15. [22] Inspired by the symmetric
feature of the furamidine structure, we further designed and synthesized a series of
diamidine compounds bearing various length of middle alkyl linker, which led to the
discovery of decamidine (Figure 1.1.1), a PRMT1 inhibitor displayed a 2-fold increase in
potency than furamidine. [23] The above studies demonstrated that diamidine structure is
an important pharmacophore for PRMT1 inhibition. In this work, we identified a novel
diamidine inhibitor, K313 (Figure 1.4.1A) using a combinatorial screening approach,
which possesses an IC50 value of 0.84 ±0.14 µM and inhibited the cell proliferation of
leukemia and ovarian cancer cell.

Figure 1.1.1. Structures of the diamidine inhibitors for PRMT1.
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1.2

METHODS

1.2.1 Virtual Screening
We used a ligand-based screening approach to identify important structural and
physiochemical properties responsible for better biological activity. It follows the
molecular similarity, QSAR and pharmacophore modeling approach to identify better
binding molecules. The virtual library containing a large number of molecules was
screened for physical and chemical properties to find small molecule compounds that
may bind to the protein with higher activity. Ligand-based screening is based on
information of structure of one or a series of known small molecules with target activity
and searches the database for new active compounds. Receptor-based screening is
performed on the database when the receptor structure is known. Small molecules use
molecular docking or ligand-based pharmacophore search methods to evaluate how small
molecules may act on the receptor structure and how well they match the binding
pockets, and finally, select hit molecules based on the score of compounds. ROCS and
EON software are used for our ligand-based screening, ROCS software screens ligands
based on the shape similarity and EON software screening is based on the similarity of
the electrostatic surface.[26-28]

1.2.2 Docking with small molecule ligand
Molecular docking has shown a very important application value in drug design.
It helps in understanding molecular recognition through energetically favorable
geometric fitting. The objective of docking studies is to model precise orientation of
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ligand in the active site. It involves sampling of possible poses of ligand within the target
active site of protein. Docking methods adopts the conformation generator algorithm (i.e.
genetic algorithm) to generate near native conformation of ligand and stochastic searches
to deal with large degrees of freedom of ligand molecules. Further an energy function
comprising van der Waals, electrostatics, solvation and entropic contribution are used to
estimate binding free energy. We used Autodock4.2 software package for our study.
1.2.3

Molecular Dynamic Simulation
Molecular Dynamics (MD) samples the position of atoms by integrating

Newton’s equation of motion. It solves the intermolecular interaction potential function
using force field and analyzes the behavior of its molecular motion. The forces acting on
each of the atoms are then calculated from the force field equation. Force field typically
calculates van der Waal interaction using Lennard Jones potential function and
electrostatic contribution using Coulomb's law. Once the force acting on each atom have
been calculated, position of each atom is moved using the Newtons equation of motion. A
series of coordinates with their velocities are stored in trajectory and analyzed for
thermodynamic kinetic properties. The evolutionary process is studied, and the
relationship between microscopic quantities (such as molecular coordinates and
velocities) and observable macroscopic measurements (such as temperature, pressure,
and heat capacity of the system). We have used AMBER 18 software package for all
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MD simulations [33]. The force filed in AMBER can be written as:

1.2.4

MM-PBSA
To study protein-ligand interactions, one of the most interesting points is the

calculation of the binding free energy. In addition to the traditional classical Free Energy
Perturbation (FEP) and Thermodynamic Integration (TI) methods, in recent years, free
energy calculation methods based on molecular dynamics (MD) sampling have been
developed, including Linear interaction energy (LIE) method and MM-PBSA method.
MM-PBSA stands for Molecular Mechanics / Poisson-Boltzmann Surface Area. This
method has been successfully applied to biological macromolecular systems, including
conformational changes in DNA, protein-protein, protein-DNA, protein-small molecule
interaction. From its name, it can be seen that the method combines the free energy into
several separate calculations, such as Molecular Mechanics representing the kinetic term.
The specific disassembly method is as follows. The thermodynamic cycle in Figure 1.2.1
is built to calculate the binding and solvating energy separately. The binding free energy
ΔGb of the receptor and the ligand can be written as follows:

In which the ΔG0solv can be calculated as follows:

And the ΔG0bind, vacuum can be calculated as follows:
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1.3

EXPERIMENTAL PROCEDURE

1.3.1 Computational

Figure 1.3.1 Workflow of the study.

The library used for the ligand-based virtual screening was the NCI Diversity set,
which contained 260071 compounds. The confirmed active inhibitor for PRMT1, DB75,
was chosen to initiate the screening procedure. Up to 50 conformers for library molecules
were generated with Omega[24, 25] (2.5.1.4, OpenEye Scientific Software). The 3D
shape-based virtual screening was performed with ROCS[26-28] (Rapid Overlay
of Chemical Structures, version 3.2.1.4, OpenEye Scientific Software). EON[27, 29]
(version 2.2.0.5, OpenEye, Scientific Software) was then used to assess the similarity of
the top 1000 compounds to DB75 from ROCS. We subsequently selected a total of 830
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compounds by merging of the top 500 hits from the ROCS and EON screen. 406 of the
top 830 compounds were available and tested for further biochemical screening. The
compound k313 were then docked into the previous reported PRMT1 homology structure
by using AUTODOCK4.2.[30] The best docking pose from AUTODOCK bound to
PRMT1 was chosen for further molecular dynamics (MD) study. All energy
minimizations and MD simulations were performed with AMBER16 in explicit solvent
(TIP3P water).[31] GAFF parameters were assigned for the ligand,[32] and the AMBER
Parm14SB parameter set[33] was applied for the protein. The systems were then
gradually brought up to 300 K and run for 50 ps in the NVT ensemble while keeping the
protein backbone restrained. The equilibration was continued for another 2 ns in the NPT
ensemble, and the harmonic restraints were gradually released. 50ns production
simulation was performed in the NPT ensemble (1 atm and 300 K) with smooth particle
mesh Ewald (SPME) electrostatics, 10 Å non-bonded cut-off and 2-fs time step. The free
energy of binding for k313 to PRMT1 was estimated using the MM-PBSA method and
normal-mode analyses for entropy as the average over the last 20 ns (2000 frames, 10
frames for entropy) from the trajectories.[34] The normal-mode analyses for entropy to
calculate the binding free energy for the protein complexes. Normal-mode analysis was
used to calculate entropy. The interaction energies were decomposed into contributions
from the ligands and PRMT1 residue pairs. CPPTRAJ module of AMBERTOOLS16[35]
and VMD[36] were used for the analysis of trajectories and structural visualization.
1.3.2 Experimental
Protein expression of Recombinant methyltransferases. Recombinant Histagged rat PRMT1, PRMT3, PRMT8 and G9a were expressed in E. coli. In brief, the
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corresponding pET28b plasmid was transformed into BL21(DE3) (Stratagene) by heat
shock method. Transformed bacteria were incubated in LB media at 37 °C for growth and
then at 16 °C for protein expression with 0.3 mM IPTG induction. Cells were harvested
by centrifuge and lysed by microfluidics cell disrupter. The supernatant containing target
protein was loaded onto the Ni-charged His6x-tag binding resin (Novagen) in equilibrium
buffer (25 mM Na-HEPES, pH 7.0, 300 mM NaCl, 1 mM PMSF, 10% glycerol (v/v) and
30 mM imidazole). Beads were washed thoroughly by washing buffer (25 mM NaHEPES, pH 7.0, 300 mM NaCl, 1 mM PMSF, 10% glycerol (v/v) and 70 mM imidazole),
and protein was eluted with elution buffer (25 mM Na-HEPES, pH 7.0, 300 mM NaCl, 1
mM PMSF, 100 mM EDTA, 10% glycerol (v/v) and 200 mM imidazole). Recombinant
GST tagged CARM1 and PRMT7 on pGEX2T or 4T plasmid were expressed in E. coli.
The supernatant containing target protein was loaded onto the Glutathione Sepharose 4B
resin (GE Healthcare) in column buffer (25 mM Na-HEPES, pH 7.0, 250 mM NaCl, 1
mm EDTA, 1 mM PMSF, and 0.1% (v/v) Triton x100). Beads were washed thoroughly
by the column, and protein was eluted with elution buffer (50 mM Na-HEPES, pH 7.0,
10 mM reduced glutathione and 1 mM PMSF). All the eluted protein solutions were
dialyzed into a buffer containing 25 mM Na-HEPES, pH 7.0, 300 mM NaCl, 10%
glycerol (v/v) and 1 mM DTT. Protein purity was checked by 12% SDS-PAGE, and
concentration was determined by Bradford assay.
Peptide synthesis. All peptide substrates were synthesized using Fmoc [N-(9fluorenyl) methoxycarbonyl]-based peptide synthesis protocol on a FOCUS XC peptide
synthesizer (aapptec, Louisville, KY). The peptide sequences are as following: H4-20biotin Ac-SGRGKGGKGLGKGGAKRHRK(biotin), Biotin-H3-20 Biotin-
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ARTKQTARKSTGGKAPRKQL, SMD1-biotin Ac-AGRGRGRGRGRGRG-biotin.
Each amino acid was coupled to the solid phase with 4 equiv of amino acid/HCTU [O(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3- tetramethyluronium hexafluorophosphate]
(Novabiochem or Chempep). The Fmoc group was deprotected with 20% v/v
piperidine/DMF, and the N-terminal amino acid was acetylated with acetic anhydride.
The peptide was cleaved from the Wang resin by a cleavage solution consisting of 95%
trifluoroacetic acid (TFA), 2.5% H2O, and 2.5% triisopropylsilane. It was then
precipitated in cold ether and pelleted by centrifugation. Crude peptides were collected
and purified using a Shimazu liquid chromatography instrument equipped with a C18
reversed-phase high-performance liquid chromatography (RP-HPLC) column, where
0.05% TFA containing water and 0.05% TFA-containing acetonitrile were two mobile
phases used in gradient purification. The identity of peptides was confirmed with
MALDI-MS.
Purchased Materials. PRMT5:MEP50 complex (part number: HMT-22-148)
was purchased from Reaction Biology Corp. Cofactor 3H-SAM was purchased from
Perkin Elmer (part number: NET155V001MC). DOT1L (HMT-11-101) and nucleosomes
(part number: HMT-35-123) were purchased from Reaction Biology Corp. Histone H3.3
was purchased form New England Biolabs (part number: M2507S).
High throughput screening (HTS) of small molecule libraries. Screening
compounds were kept at 10 µM and 100 µM in the assay. The HTS by scintillation
proximity assay (SPA) method was performed on 96-well plate format. The DMSO
solution of the inhibitors was at 10 or 20 mM, then diluted with ddH2O to 50 or 500 µM.
Diluted inhibitor solutions (3 µL) were incubated with 9 µL mixture containing H4-20-
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Biotin peptide, [3H]-SAM and 2X reaction buffer, then the enzyme (3 µL) was added to
initiate the reaction. The reaction buffer contains 50 mM HEPES, 10 mM NaCl, 0.5 mM
EDTA, 0.5 mM dithiothreitol (DTT) at pH 8.0. The final concentrations of the enzyme,
3

H-SAM, and H4-20-Biotin are 0.02, 0.5, and 1 μM, respectively. The concentrations of

[3H]-SAM, and biotinylated H4 peptide in the assay were kept at balanced condition (≈
Km) to indiscriminately identify competitive, uncompetitive and noncompetitive
inhibitors. The mixtures were incubated at room temperature for 8 min before it was
quenched with15 µL isopropanol. After mixing with 5 µL of 20 mg/mL streptavidincoated SPA beads, the plates were incubated in dark for 30 min and detected by a
Microbeta2 scintillation counter (Perkin Elmer). The positive control was carried out with
the corresponding DMSO dilute surrogate, and the background control only contained
3

H-SAM, H4-20-biotin peptide and DMSO. The reported data was based on the average

of two experiments.
Biochemical selectivity assay. The single point screening and IC50 values of
inhibitor hits over a panel of methyltransferases were determined. The reaction condition
for each enzyme is listed in the following table. The reaction time was controlled under
initial rate conditions for reaction yields of less than 10%. The reaction buffer contains 50
mM HEPES pH 8.0, 10 mM NaCl, 0.5 mM EDTA, and 0.5 mM DTT for all the PRMTs.
The reaction buffer contains Tris 50 mM pH 9.0, 5 mM MgCl2, 4 mM DTT for all the
lysine methyltransferases (G9a and DOT1L). The inhibitor solutions were made at 10 µM
for single-point screening or as a series of dilution for IC50 determination. For the
methylation reaction using biotinylated peptides, the procedure was similar to the SPA
method described above. The methylation reaction using protein substrates was carried
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out by radioactive filter plate assay in a 96-well format. Protein substrate and [3H]-SAM
were preincubated in the reaction buffer for 2 min prior to initiation of the methyl transfer
reaction by adding the enzyme (30 µL total volume). The reaction was quenched by 10
µL of 30% TCA, followed by spotting the reaction mixture on a 96-well 0.2 µm filter
plate (Multiscreen filter plates, Millipore cat. Number: MSFBN6B10). Then 40 µL of
10% TCA was added for protein precipitation and the plate was incubated at 4 oC for 20
min. After the plate was washed with 100 µL of 10% TCA for 4 times and 100 µL of
100% ethanol once, they were immersed in 50 µL of liquid scintillation mixture
(Microscint PS, PerkinElmer). Scintillation counting was performed by a Microbeta2 to
measure the amount of methylated products. The positive control was carried out with the
corresponding DMSO dilute surrogate under the same condition, and the background
control only contained [3H]-SAM, protein substrate, and DMSO. IC50 values were
obtained by quantification of formed product at various concentrations of inhibitors, and
fit with equation 1. The relative activity of the protein in the presence of the inhibitor is
normalized to the value of product formation without inhibitor present, n is hill
coefficient. The reported data was based on the average of two experiments.
Table 1. Reaction conditions for the methyltransferase panel.
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Protein

Substrate

Cofactor

Reaction time

PRMT1, 20 nM

H4-20-biotin, 1 uM

SAM, 0.5 uM

8 min, RT

PRMT3, 20 nM

SMD1-biotin, 1 uM

SAM, 0.5 uM

10 min, RT

CARM1, 20 nM

H3.3 protein, 0.4 uM

SAM, 0.5 uM

120 min, RT

PRMT5, 20 nM

H4-20-biotin, 1 uM

SAM, 0.5 uM

8 min, RT

PRMT6, 40 nM

SMD1-biotin, 1 uM

SAM, 0.5 uM

30 min, RT

PRMT7, 40 nM

SMD1-biotin, 1 uM

SAM, 0.5 uM

120 min, RT

PRMT8, 20 nM

H4-20-biotin, 1 uM

SAM, 0.5 uM

8 min, RT

G9a, 20 nM

Biotin-H3-20, 1 uM

SAM, 0.5 uM

30 min, RT

𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = 1/(1 + ([𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟]/𝐼𝐶50)𝑛 )

(1)

Mechanism-of-inhibition studies. Experimental conditions for the SAM or
peptide competitions in a 30-μL total volume in 96-well format were similar to those for
the IC50 experiments. K313 concentration was in two-fold dilutions from 10,000 to 312.5
nM. 3H-SAM was serially diluted three-fold a top concentration of 4.5 µM. Reactions
were initiated by the addition of 20 nM enzyme and 1 µM peptide. For peptide titration
assay, H4-20-biotin was serially diluted three-fold with a top concentration of 4.5 µM.
Reactions were initiated by the addition of 20 nM enzyme and 0.5 µM 3H-SAM.
Reactions were incubated at room temperature for 10 min, and then quenched by the
addition of 30 μL per well of isopropanol.
IC50 determination of PRMT1 inhibitors in ovarian cancer cells. OVCAR-3
(ovarian cancer) cells (ATCC, Manassas, VA, USA) were plated at 6,000 cells per wellin
a 96-well plate in RPMI (Corning, Corning, NY, USA) supplemented with 10% FBS
(Atlanta Biologicals, Flowery Branch, GA, USA) and 10 mL penicillin/streptomycin
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(Thermo Fisher, Waltham, MA, USA). The following day, cells were serum starved in
RPMI without FBS and incubated overnight. Then, cells were treated in triplicate wells
with K313 and DB75 at ten serially-diluted concentrations in uM: 200, 100, 50, 25, 12.5,
6.25, 3.1, 1.6, 0.8, and 0 (control). The control condition contained 2 uL DMSO per 1 mL
of media as this was the solvent for all compounds. Cells were treated at these
concentrations every 48 hours for a total of three treatments over 7 days. The IC25, IC50,
and IC75 values for each compound were calculated in their respective cell lines using the
dose response curve generated by the data in GraphPad Prism 7.
OVCAR3 cell treatment, lysate extraction and western blot analysis.
OVCAR-3 were plated in a 2 6-well plates at 400,000 cells per well in RPMI (Corning,
Corning, NY, USA) supplemented with 10% FBS (Atlanta Biologicals, Flowery Branch,
GA, USA) and 5 mL penicillin/streptomycin (Thermo Fisher, Waltham, MA, USA) and
incubated overnight. Cells were serum starved the following day in RPMI without FBS,
but containing penicillin/streptomycin, for 24 hours. Cells were treated at IC25, IC50 and
IC75 concentrations of DB75 and K313 respective to each cell lines and control
condition contained DMSO. Cells were treated every 48 hours for 5 days and protein was
extracted using RIPA Lysis Buffer (Thermo Fisher, Waltham, MA, USA) with 100x
Protease/Phosphatase inhibitor cocktail (Thermo Fisher, Waltham, MA, USA) with
sonication and stored at -80°C. Protein quantification was performed using the Pierce
BCA Protein Assay (Thermo Fisher, Waltham, MA, USA). Protein lysates from IC25,
IC50, and IC75 treated OVCAR3 (ovarian cancer) cells with DB75 and K313 were
combined with 6x SDS sample buffer and boiled at 95°C for 5-10 minutes. Samples were
loaded onto the SDS-PAGE gel and run at 80V for 30 minutes followed by 100V for an
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additional 1 hour. Gels were transferred onto a PVDF membrane for 2 hours at 100V, 0.6
Ampere on ice and blocked using 5% dry milk in 1x TBS-T for one hour. Each
membrane was then incubated in a primary antibody, 1:1000 Gapdh or 1:500 PRMT1,
1:500 ADMA histone, 1:500 ADMA pan, or 1:500 SDMA pan, overnight. The blots were
then washed with 1x TBS-T 3 times for 15 minutes each time and incubated in 1:10,000
secondary anti-rabbit antibody for one hour. The blots were rinsed with 1x TBS-T
following secondary antibody 3 times for 15 minutes each time. The blots were imaged
using Li-Cor Image Studio Imager and quantification was performed using Image J. All
figures were assembled in Microsoft PowerPoint or GraphPad Prism 7.

1.4

Results and Discussion
To gain a better diversity of the diamidine moiety, a ligand-based virtual

screening was applied, in which the rigid, crescent and planar structure of a PRMT1selective furamidine (Figure 1.1.1) was used as the structural template. Both charge and
shape similarity filtration was applied, which resulted in a focused compound library
containing the top 406 hits out of the NCI Diversity Set (total of 260071 compounds).
The 406 compounds (K1 to K406) from the focused library were subject to a biochemical
high throughput screening (HTS) using a scintillation proximity assay (SPA) format.
Inhibitory activities of the 406 compounds against PRMT1, representing type I PRMTs,
and PRMT5, representing type II PRMTs, were evaluated. (Figure 1.4.4). In this primary
HTS, the top 33 compounds inhibited PRMT1 activity to less than 50% at 10 µM were
identified as initial hits, which potentially possess better potency then furamidine (IC50 =
9.4 ±1.1 µM) . Further validation experiments of these PRMT1 inhibitor hits led to the
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lead inhibitor, K313, with an IC50 of 0.84 ±0.14 µM for PRMT1 (Figure 1.4.1A and C).
To obtain more structure analogs of K313, we conducted a second-round virtual
screening search on the NCI Diversity Set using the established method, in which the
structure of K313 as filtration template. The K313-derived focused library contained 89
compounds (K415 to K503), which were screened at 10 µM and 100 µM against PRMT1
in the same SPA-HTS format. In this secondary screening, 14 compounds were able to
inhibit the PRMT1 activity to less than 50% at 10 µM (Figure 1.4.1B). However, K313
still possessed the best potency against PRMT1 (IC50 = 0.84 ±0.14 µM), followed by
K465 (IC50 = 2.4 ±1.0 µM, Figure 1.4.6A). Further, the inhibitory activity of K313
against a methyltransferase panel containing seven PRMT isoforms (PRMT1, PRMT3,
CARM1, PRMT5:MEP50, PRMT6, PRMT7 and PRMT8) and a lysine methyltransferase
(G9a) was determined (Figure 1.4.1D). The selectivity profile indicates that K313 is a
strong PRMT1 inhibitor, more potent than it is for the other methyltransferases in the
panel (Figure 1.4.1D). The selectivity of less potent PRMT1 hits from the primary
screening was also measured, among which K413 is selective against CARM1 and K336
showed a certain extent of selectivity against type I PRMTs, while K278 and K309 are
less selective (Figure 1.4.5).
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Figure 1.4.1 Identification of compound K313. A. Structure of K313. B. Twoconcentration (10 µM and 100 µM) screening result of the K313-derived library, n = 2. C.
IC50 curves and values of K313 and furamidine, n = 2 for each compound shown. D. K313
selectivity panel screening at 10 μM and corresponding IC50 values.

From the two focused libraries use for primary and secondary screenings, 30 most
structurally-related compounds were chosen for SAR analysis. These compounds were
categorized into three series according to their central frame structures (Figure 1.4.6,
1.4.7). In series 1, compounds share two indene-like cores connected by butene or butyl
linkers. The substitution of the 5-membered ring affects the activity of the compounds,
and K465 showed the lowest IC50 at 2.4 ±1.0 µM among all (Figure 1.4.5). The
additional methyl group on the double-bond linker of K457 did not bring significant
change on the potency, comparing to K467 (Figure 1.4.5A). The replacement of the
diamidine group with imidazole in K473 decreased its inhibition compare to K464
(Figure 1.4.5B). The cis conformation in K466 slightly reduced the potency than the
trans compound K465 (Figure 1.4.5C). Flexible linker was generally not favored,
comparing K461 to K465 or K466, and K458 to K469 (Figure 1.4.5D). In series 2, there
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is a benzene ring connected with an indene-like core (Figure 1.4.6). Similar to series 1,
substitution of the 5-membered ring altered the potency of the inhibitors (Figure 1.4.1A),
and the imidazole side group was not as favored as the amidine group (Figure 1.4.1B). In
series 3, inhibitors bearing different lengths of the linkers are listed (Figure 1.4.7), and
the shorter linker (K309 and K489) is more preferred than the four-carbon diene linker
(K475 and K481).
To explore the K313/PRMT1 interactions, we conducted molecular modeling
studies by means of docking and MD simulations. Following MD simulations, the
binding energy for K313 was calculated via MM/PBSA. The substituents on the linker of
K313 significantly increased its binding affinity. As shown in table 2, the estimated
binding energy of K313 (−37.90 kcal/mol) was less than that of DB75 (−28.9 kcal/
mol),[37] in agreement with the experimental IC50. In order to elucidate the detailed
interactions responsible for stabilizing K313 in the PMRT1, the binding free energy was
decomposed individual contributions per residue level of the PMRT1. As shown in
Figure 1.4.2, the diamidine moiety of K313 inserts into both the SAM adenosine binding
site and methionine binding site which differs from the previously reported binding mode
of DB75 to PRMT1. One amidine group, which deeply inserted into the cofactor
methionine pocket, interacted with the Gly-rich loop of PRMT1 (residues G78 and G80)
via hydrogen bonds with the side chain of D76 and the backbone carbonyl group of S79.
Additionally, the second amidine group and adenosine moiety of K313 is embedded by
several hydrophobic residues (Val77, Try35, Phe36, and Tyr39, YFXY motif), that are
responsible for hydrophobic interactions (π–π interactions). This deep placement may
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account for the stronger binding K313 with PRMT1.

Figure 1.4.2 Binding pocket detail of K313 bind to PRMT1

TABLE2 Estimated Binding Free Energy in Different Terms.

In order to obtain information about inhibition mode of K313 on PRMT1, the IC50
values were determined by titrating peptide substrate or SAM concentrations while
keeping the other component at a fixed concentration in the reaction. K313 showed a
pattern of noncompetitive inhibition with respect to the peptide substrate and the cofactor
SAM, as demonstrated by the minimal changes of the IC50 values on the increasing
peptide substrate or cofactor SAM concentrations. The slight increase of the IC50 value at
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a high concentration of SAM may indicate that K313 is partially competitive with SAM,
in accordance with the docking studies that K313 occupied the cofactor binding site.
The anti-cancer activity of furamidine was previously demonstrated in leukaemia
cells. [22, 38] Significant inhibition of the cell proliferation was observed in several
leukemia cells, after treating with 20 μM of furamidine for 72 h. [38] It also inhibited the
methylation of PRMT1-mediated putative RNA-binding protein 15 (RBM15) in MEG01
cells. [22] Therefore, in this work, we first evaluated the anti-cancer activity of K313 in
leukaemia cell lines. The cellular IC50 values of K313 ranges from 1.03 µM to 2.27 µM
after three-day treatment in MEG01, CMK, K562 and HEL cell lines (Figure 1.4.3, A and
C). The cellular IC50 values of K313 after four-day treatment showed a slight decrease,
ranging from 0.82 µM to 1.41 µM for the four leukaemia cell lines (Figure 1.4.3, B and
C). The inhibition of cellular activity of PRMT1 was evaluated by the methylation level
of its substrate using immunoblotting. At 100 nM and 200 nM of K313 treatment in the
MEG01 cells, the methylation of RBM15 was significantly reduced in a dose-dependent
manner. A decrease in signal intensity was also observed in pan-asymmetric methylation
(α-Asym24).
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Figure 1.4.3 K313 inhibits the proliferation of leukemia cell lines via blocking of
PRMT1 activity. (A−C) K313 inhibited leukemic cell growth. Serial diluted K313 was
added to the MEG01, CMK, K562, and HEL cell cultures and cell growth was measured
by viability assay. As a control, the cells were treated with the same volume of DMSO.
Sensitivity curves of day 3 (A) and day 4 (B) are plotted based on viability assay results
and IC50 was calculated (C). (D) The arginine methylation level of K313-treated MEG01
cells. MEG01 cells were cultured with the presence of control or K313. Cell extract was
harvested after 24 h of treatment, and samples were resolved by SDS−PAGE. Arginine
methylation status was detected by using anti-methyl-R antibody Asym24. PRMT1
activity was measured by the methylation status of substrate protein RBM15. Equal
loading was confirmed by Ponsceau S staining.
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Figure 1.4.4 Single concentration (10 µM) screening result of the furamidinederived library against PRMT1 and PRMT5.
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Figure 1.4.5 Selectivity profiles of selected hits from the furamidine-derived
library.
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Figure 1.4.6 Structure activity relationship of the K313 analogs, series 1.
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Figure 1.4.7 Structure-activity relationship of the K313 analogs, series 2.

Figure 1.4.8 Structure-activity relationship of the K313 analogs, series 3.
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1.5

Conclusions
From the estimated free energy calculation and conformation analysis, we can

conclude some key factors contributing to the high affinity of K313. One amidine group
inserted into the cofactor methionine pocket interacted with PRMT1 via H bonds, each
interaction contributes for around -7 to -3 kcal/mol. The second amidine is embedded by
several hydrophobic residues that interact via π–π interactions with the K313 aromatic
backbone. Each pair of hydrophobic interaction contributes around -2 to -1 kcal/mol to
the binding energy. Estimated binding free energy is −37.90 ± 11.59 kcal/mol, in
agreement with the IC50 value, indicating K313 can inhibit PRMT1 with high activity.
Treatment of OVCAR-3 cells with DB75 and K313 shows a strong selectivity of
K313 for targeting cancer cells with an IC50 value of 2.49 µM at 7 days . Based on the
data collected from cell viability studies, OVCAR-3 cells were treated at IC25, IC50 and
IC75 concentrations shows that K313 targets arginine methylation in the cell, with the
latter target undergoing a dose-dependent decrease in expression with increasing K313
treatments. Quantification of the Western blot confirms that arginine methylation is likely
a direct target of K313. Interestingly, there is more decrease of pan ADMA level treated
by K313 compare to that of DB75; however, the decrease of histone specific ADMA
(H4R3me2a) level is more significant if DB75 treatment group. There is also a decrease
of SDMA level upon treatment, and K313 shows less selective comparing to DB75,
which is in accordance with their enzymatic inhibitory selectivity (IC50 of K313 for
PRMT5 is 6.8 ± 0.77 μM). It is yet to be determined which specific methylated proteins
may be contributing to decreases in cell viability.
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CHAPTER 2. EXPLORING THE INFLUENCE OF MULTIPLE MODIFICATIONS ON
THE HISTONE H4-PRMT BINDING

Abstract
Histone code is the post-translational modification patterns appear on histone,
believed in regulating transcription and many other cellular events. Protein Arginine
Methyltransferases (PRMTs) are a family of enzymes that important in establishing
histone codes by methylating the guanidino group of Arginine. They are also regulated by
the histone codes. In this study, we explored the mechanism of how the post-translational
modifications on H4 tail peptide affect the activity of PRMTs.

2.1

INTRODUCTION

2.1.1 Histone and Histone Posttranslational Modification Patterns
There are many types of histones, most of which are composed of a globular
region and protruding from the basic amino acid composition of histone tails in vitro.
Every two sets of H2A, H2B, H3 and H4 form an octamer. DNA in eukaryotes is
entangled on this octamer to form a nucleosome. Histone H1 binds to connecting DNA
between nucleosomes, make the nucleosomes stay closer to each other one by one. Posttranslational modification of histones is not only closely related to chromosome
remodeling and functional status, but also plays an important role in the process of
determining cell death, cell growth, and carcinogenesis [1]. It also plays a direct role in
the process of cell death, DNA damage repair, DNA replication, and reorganization [2].
Histone acetylation is closely related to the activation and suppression of gene
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transcription. Generally, histone acetylation activates gene transcription, while
deacetylation causes gene transcription to be suppressed. 5 histones (H1, H3, H2A, H2B,
and H4), except for the N-terminal of H1 that rich in hydrophobic amino acids, Cterminal is rich in basic amino acids, the rest 4 species are rich in basic amino acids (eg,
arginine, lysine) on N-terminal, the C-terminus is rich in hydrophobic amino acids (such
as valine and isoleucine). The C-terminal domain in histone has a motif that interacts
with histone molecules. The N-terminal has highly variable regions that rich in lysine,
can interact with other regulatory proteins and DNA. Histone N-terminal 15 to 38 amino
acid residues at the end of the tail are the main post-translational modifications sites to
regulate the biological function of DNA [3]. Histone post-translational modifications
include acetylation and deacetylation, phosphorylation and dephosphorylation,
methylation and demethylation, ubiquitination and dephosphorylation, and so on.
Modification on a single residue often is not enough for independent regulation, different
covalent modifications of one or more histone tails or a combination of a modified
cascade is then formed. They work together synergically or antagonistically. These
diverse modifications and their spatial combinations relating with biological functions
work as an important epigenetic sign or language, also known as "Histone code" [4, 5],
can be used in different environments to be recognized by a series of specific proteins or
protein complexes, which translates this code into a specific chromatin state in order to
achieve the regulation of specific genes. While the DNA sequence does not change, the
expression of the gene changes with histone modification and DNA methylation,
chromosome remodeling, and non-coding RNA regulation, and this change can also
progress through mitosis and meiosis inheritance, a way of inheritance that known as
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"epigenetics." Histone code expands DNA sequence self-contained genetic information
and constitutes important epigenetics signals.
2.1.2 Functions and Activities of PRMT Family
Arginine methylation is a widely existing post-translational modification that acts
as an epigenetic regulator of transcription and also extensively involved in other
processes such as precursor mRNA splicing and translation, DNA damage signaling, and
cell signaling. The arginine methylation process is completed under the catalysis of
protein arginine methyltransferase (PRMT). PRMT catalyzes the transfer of the methyl
group in the substrate S-adenosylmethionine (SAM or AdoMet) to the guanidyl N of
arginine. In cell growth, inflammatory response [6], tumorigenesis, PRMT plays an
important role in the process of development [7], tumor invasion [8], and T-lymphocyte
activation [9]. PRMT is relatively conservative in evolution, and it is widespread in
unicellular eukaryotic yeast to higher animals and plants [6].
To date, 11 PRMT family members (PRMT1 ~ 11) have been reported in humans
[10], of which PRMT1, PRMT2, PRMT3, PRMT4 / CARM1, PRMT6, and PRMT8
belong to the type I protein arginine methyltransferase; PRMT2, PRMT5, PRMT7, and
PRMT9 belong to type II enzymes, and methyltransferase activity of PRMT10 and
PRMT11 has not been reported [11]. The results of protein sequence alignment showed
that all 11 PRMTs have conserved catalytic domains, including motif I, post-I, motif II
and motif III, and "double E" and THW loop [12]. The similarities of I, post-I, II, and III
motifs of PRMT9 are low compared to several other PRMTs, and there is no THW loop
[21]. PRMT7 and PRMT10 have two catalytic functional domains [13]. These different
PRMT members have an additional N-terminal or C-terminal to distinguish them
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functionally. For example, PRMT2, PRMT3, and PRMT8 have SH3, zinc fingers, and
myristoylation domains, respectively; PRMT4 has a unique C-Terminal region; and
PRMT9 and PRMT11 each have an F-box involved in protein interactions. Although the
functions of these N-terminal and C-terminal domains are not fully understood, the
deletion of these domains will lead to reduced PRMT stability and enzyme activity [14].
PRMT will catalyze the production of 3 types of methylation products: (1)
monomethylated arginine (MMA), which is an intermediate of dimethylation, which is
usually unstable and will continue to methylate to produce a stable two Methylated
product, PRMT7 can only catalyze the production of MMA; (2) Symmetrically
dimethylated arginine (SDMA), which produces ω-NG, N'G-symmetrical two under the
catalysis of PRMT5 and PRMT9 Methylation products; (3) asymmetrically dimethylated
arginine (ADMA), which produces ω-NG, NG-asymmetric under the catalysis of
PRMT1, PRMT3, PRMT4 (CARM1), PRMT6 and PRMT8 product dimethylation [15].
PRMT is not only closely related to the normal growth and development process but also
regarded as a potential drug traget[16].
PRMT1 is the most important type I enzyme in mammals. In rat fibroblasts and
mouse liver, the enzymatic activity of PRMT1 accounts for about 85% of the total protein
arginine methyltransferase activity [17]. PRMT1 was screened by yeast two-hybrid as an
interacting protein with TIS21 and BTG1 [18]. Subsequent research found that PRMT1
as a nuclear receptor coactivator activates the transcription of the corresponding target
site by catalyzing the methylation of histone H4R3 [19]. PRMT1 is widely present in the
cytoplasm and nucleus [20], and is involved in multiple life processes such as
transcription, DNA damage repair, protein localization, and signal transduction through
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methylation of histones and various non-histones [21]. PRMT5 is currently the most
important type II protein arginine methyltransferase, which catalyzes the formation of
symmetric arginine dimethylation. PRMT5 was obtained by yeast two-hybrid screening
as a protein that interacts with Janustyrosine kinase 2 (Jak2) [22]. Studies in animals have
shown that PRMT5 is localized in the cytoplasm and nucleus and is involved in the
formation of multiple complexes. In the cytoplasm, PRMT5 is present in methylosome,
and together with the core components Sm proteins regulate the assembly of small
nuclear ribonucleoproteins (snRNP) [23]; in the nucleus, PRMT5 is able to interact with
multiple transcriptional repression complexes to regulate gene transcription through
methylation of histones (H2AR3, H3R8, H4R3) and non-histones substrates[24]. In 2014,
Kim et al. [25] found that PRMT5 inhibited the expression of transposons such as LINE1
and IAP by methylating H2AR3 and H4R3 in primitive germ cells, suggesting that it can
maintain genomic integrity during epigenetic reprogramming.
2.1.3 Structural Comparison of PRMT1 and PRMT5
The crystal structure of the PRMT family elucidates the molecular mechanism
that PRMTs catalyze arginine methylation. At present, the PRMT structural analysis in
various species includes Hmt1 [17] of yeast, PRMT1 [26] of rat, PRMT3 [18] and
PRMT4 / CARM1 [27], PRMT5 [28] of nematodes and Arabidopsis thaliana PRMT10
[29], human PRMT1 [30] and PRMT5 [31] (Figure 2.1.2) . The catalytic structure of
PRMT shows a well-conserved structure. The N-terminal of the central region contains a
classic Rossman fold and two α-helixes. This is the binding site of AdoMet and the most
conserved region in the PRMT protein family. The C-terminal of the central region has
Some β sheets that are folded to form a barrel-like structure, which is a unique structure
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of the PRMT family. After folding, it is opposite to the N-terminus. The slit formed
thereby provides a binding and catalytic region for the protein substrate.
All PRMT arginine substrate pockets have a commonly conserved motif known
as the double E loop, consist of two glutamic acid residues. The two glutamic acid
residues fill the surface inside the binding pocket with negative charges, thus can capture
the target peptide with positively charged guanidine groups in the arginine sidechain. The
catalytic mechanism of PRMT involves the recognition process by these two glutamic
acid residues, not only enhancing the nucleophilicity but also locating the guanidine to a
favorable position for transferring the methyl group from cofactor. The Glu153
(numbered as it in HsPRMT1) from the double E loop helps align via electrostatic
interactions, while Glu144 involving via hydrogen bonding. This PRMT1 catalyzing
reaction is mainly caused by a comparison of the methyl groups of guanidine and
AdoMet, and guanidine deprotonation is not critical for nucleophilic attack. The
interactions between peptide and PRMT1 are mainly happening on the PRMT1 double E
loop and THW motif residues. The His293 on the THW motif forms a hydrogen bond
with the main chain carboxyl group of the H4R3, and the main chain carboxyl group of
Glu144 / Glu153 forms an H bond with the guanidine group of arginine. It can be seen
that for all type 1 PRMTs, residues in the THW motif and in the double E loop are
involved in peptidyl arginine recognition. The crystal structure of the HsPRMT5 peptide
complex includes the first 8 residues of the H4 peptide, as well as the position of
substrate Arg3. This crystal structure shows that the H4R3 forms a salt bridge with
Glu435 and Glu444 of the double E loop. Glu435 / 444 may be involved in the
deprotonation and activation of the ω-N nitrogen atom for methyl transfer. H4 peptides
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are also fixed by the interactions with PRMT5 residues from the flexible linker region
that connects the peptide backbone, the N-terminal TIM barrel and the catalytic AdoMet
methyltransferase domain. This recognition cluster greatly promoting hydrophobic
interactions at this site.[32] To sum up, the double-E and THW loop form the binding
pocket in both PRMT1 and PRMT5, the linker loop in PRMT5 makes the pocket area
different (Figure 2.1.1).

Figure 2.1.1 Binding pocket structural alignment, PRMT5 is marked by green and
PRMT1 is marked by purple.
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Figure 2.1.2 Structure comparison of human PRMT1 and human PRMT5.

2.2

METHODS

2.2.1 Flexible peptide docking with Rosetta
Rosetta FlexPepDock is a peptide docking method recently developed in the
Rosetta software package. It includes three docking modes, namely, an optimization
protocol, an ab-initio protocol, and PIPER-Flexpepdock. The main purpose of the
refinement protocol is to optimize the low-precision peptide-protein model to a highprecision model. Therefore, the initial conformation of the peptide should be as close to
the natural conformation as possible. This protocol uses Monte Carlo minimization to
optimize the backbone architecture and peptide in rigid model. At the same time, the
flexibility of the sidechains of the peptide and protein receptor is also considered in the
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docking process. When the structural information of the peptide is unknown,
FlexPepDock's ab-initio prediction mode is needed. This model first uses a Monte Carlo
optimization method to dock a fully extended peptide chain near the binding site of the
receptor protein, and randomly generates a series of initial peptide conformations at the
interaction interface. The precision models are further optimized for energy, and finally,
the conformation of all complexes was quantitatively evaluated according to the energy
scoring function. [33]
2.2.2 Free Energy From Thermodynamic Integration
The Thermodynamic Integration (TI) calculates the free energy difference
between the reference state and target state by a parameter λ serving as additional nonspatial coupling coordinates in the potential function. With the coupling of λ, the free
energy difference between the reference state and target state can be calculated as
follows:

In the equation, V (λ) is a λ coupling potential function corresponding to the
potential of reference state at λ = 0 and then the potential of target state at λ = 1.
Integration is the combined potential function for a given λ value. Because of the obstacle
for performing the analytical integration for state potential function, it uses an integration
in which simulations are performed on different discrete λ points or "windows" to
calculate the numerical integration. The advantage of TI calculations is multiple
independent MD simulations can run with a fixed lambda value for better sampling.
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When efficiency needs to be improved, this can enable efficient parallelization and add
additional lambda windows.[36]

Δ GC

Δ GB

Δ GA

Δ GD

Figure 2.2.1 Scheme showing the thermodynamic cycle of TI
The thermodynamic integral calculation is a series of TI calculations using
thermodynamic cycles, as shown in Figure2.2.1, to calculate the free energy difference
between two systems with different chemical compositions, which cannot be verified
experimentally, observable results must be physically connected. Processes A and B
represent the binding of two different ligands to proteins. Processes C and D are
transformations between modified and non-modified ligands with proteins or solvate in

41

water. TI calculations can be used to compute relative binding free energies follows
ΔGC - ΔGD = ΔGA - ΔGB.

Figure 2.2.2 The transformation of SER to phosphorylated serine SEP.

2.3

EXPERIMENTAL PROCEDURE

Structure Construction

PDBID: 4GQB, HsPRMT5; 6NT2,

Peptide Docking

2500 conformations each run each structure

Cluster

Centroid and lowest energy conformation of

Mutations

S1ph R3me K5me K5ac

TIMD

MD/MMPBSA

Binding Free Energy

Estimated free energy / relative difference

Figure 2.3.1 Workflow of the study
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For building the initial structure for docking, the human PRMT5 crystal structure
(PDB ID: 4GQB) with the first 8 residues of H4 is taken as the reference of the binding
pocket. Then the tail residues other than the first 8 of H4 are arbitrarily spliced after the
LYS8 residue with an expanding conformation. For PRMT1, the structure is based on the
human PRMT1 crystal structure (PDB ID: 6NT2). PRMT1 crystal structure does not
have substrate peptide within it. The first 8 residues are placed by the structural
alignment of the pocket region with the PRMT5 crystal structure, and the tail residues are
set up in the same manner as in PRMT5. All the structure construction operation is
performed with PyMol and Chimera.
Peptide flexible docking is performed with Rosetta ab-initio protocol. For PRMT5,
the first 8 residues come from crystal residue is constraint with fixed α carbon to hold the
original structure during docking. PRMT1 is constraint with the major interaction of
SER3 with GLU444 and GLU432 by atom-pair. Each run generated 2500 conformations
for each residue. Conformation pool is clustered by AmberTool CPPTRAJ,
cutoff(epsilon) is 0.5a. Best conformations are selected among the centroid structures
from clustering and finally picked in consideration of the lower Rosetta score.
Docking structure mutation is introduced by modify residue names in the PDB file
and trim extra atoms or atoms with different names in the mutated residue parameter in
the meantime. Non-canonical residue parameterization follows the Antechamber
protocol. Gaussian09 takes the partial charge calculation with HF 6-31G optimization,
then RESP charge data is written into parameters by Antechamber.
Molecular dynamics simulations are conducted with Amber18. AMBERTOOL
tLeap generates the modified peptide topology and coordinator files, and missing heavy
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atoms within the mutation site will completing follow the parameters by tleap. PRMT-H4
complex structures are set with explicit solvent (TIP3P water), fill in the periodic box
size of 10 Å exceeding the van der waals boundary of the complex. GAFF parameters,
together with parameters created by antechamber protocol, were assigned for the noncanonical residues, and the AMBER Parm14SB parameter set was applied for the protein.
The systems were then gradually brought up to 300 K and run for 50 ps in the NVT
ensemble while keeping the protein backbone restrained. The equilibration was continued
for another 2 ns in the NPT ensemble, and the harmonic restraints were gradually
released. 50ns production simulation was performed in the NPT ensemble (1 atm and 300
K) with smooth particle mesh Ewald (SPME) electrostatics, 10 Å non-bonded cut-off and
2-fs time step.
The production trajectories then clustered with CPPTRAJ, the centroid structure
of the most populated cluster is used for illustrating the stable interactions among the
complex. The free energy of binding for k313 to PRMT1 was estimated using the MMPBSA method and normal-mode analyses for entropy only on the region with stable
RMSD for each trajectory respectively (2000 frames each in total). The interaction
energies were decomposed into contributions by residue. CPPTRAJ module of
AMBERTOOLS18 and VMD were used for the analysis of trajectories and structural
visualization.
TI free energy calculation proceeds in parallel with the MM-PBSA as a
supplemental for the better detail comparison. Consider that all the modification sites
located on the first 5 residues, only the first 7 residues out of the 20 residues from the
peptide are taken into the calculation to avoid the disturbing on free energy by the floppy
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tail. For each modification, the whole modified residue and non-modified residue are set
with a TI mask and calculate with the soft-core method in AMBER18. For each run, 11
windows are set by λ from 0.0 to 1.0 with 0.1 offsets. One-step transformation with both
VDW and charge is used during the transform from non-modified peptide to the modified
peptide. The H4-PRMTs complex and peptide itself are solvated with the same TIP3P
water box that fits with the complex size to keep the solvent energy constant. GAFF
parameters together with parameters created by antechamber protocol were assigned for
the non-canonical residues, and the AMBER Parm14SB parameter set was applied for
other residues. The systems were then gradually heated up to 300 K and simulated for 50
ps in the NVT ensemble while keeping the protein backbone restrained. The equilibration
was continued for another 2 ns in the NPT ensemble, and the harmonic restraints were
gradually released. 5ns production simulation was performed in the NPT ensemble (1 atm
and 300 K) with smooth particle mesh Ewald (SPME) electrostatics, 10 Å non-bonded
cut-off and 2-fs time step. The TI free energy for each window are averaged by step, and
then the integration is performed on the linear plot. Each trajectory is clustered with
CPPTRAJ, the centroid structure of the most populated cluster is used for visualization.
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2.4

RESULTS AND DISCUSSION

Rosetta Score

Rosetta Score

2.4.1 Flexible Peptide Docking

a.

RMSD

b.

RMSD

Figure 2.4.1 Docking result plot by Rosetta score-RMSD. a, docking with PRMT5; b,
docking with PRMT1.
FlexPepDock gives thousands of refined conformation for each structure, the plot
of RMSD versus Rosetta score showing the docking results distribution is shown in
Figure 2.4.1. For PRMT5, the strict constraint limited the searching space, the maximum
RMSD of the major band is around 4Å. The constraint score term also contributes
heavily to the total score, which makes the distribution bind presents a flat base around 1500. The total score also ranges lower compare to PRMT1 because of the dominance of
the restrain. The docking on PRMT1 entitled with larger searching space, the distribution
on RMSD is more separate. The highest RMSD of the major bind comes to 5.5,
potentially showing 4 clusters in the plot. Clustering then performed with DBSCAN
algorithm with cutoff 0.1. For PRMT1, clustering by RMSD gives 4 major clusters, the
most populated one constituted by 936 points and centered at RMSD of 1.207 Å. For
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PRMT5, 8 clusters are identified with 1569 points and centroid at RMSD 1.904 Å,
presenting a more concentrating pattern.
b.

a.

c.

Figure 2.4.2 PRMT5 Docking result. a, docking pose of largest cluster centroid
conformation, protein surface is colored by charge, blue stand for the positively charged
region and red is negatively charged region; b, Binding pocket detail; c, Major
interactions of the peptide docking.
The reasonable docking pose indicates a surface-binding conformation for H4
binds with PRMT5. The space surrounding by TIM barrel and β barrel forms a groove
exposing the positively charged residue on the surface, providing the anchor for the rich
positively charged H4 to bind. Taking a step closer into the active pocket, the H4R3
maintains a strong interaction with two glutamaic acids. H4K5 forms hydrogen bond with
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R310 and H4K8 forms hydrogen bonds with E489 sidechain and L308 backbone
carbonyl group. The hydrophobic linker forms short α helix with only one fold, and the
positively charged Lys15 and Lys20 on the tail form hydrogen bonds with E261 and
E285, respectively.
a.

b.

c.

Figure 2.4.3 PRMT1 Docking result. a, docking pose of largest cluster centroid
conformation, protein surface is colored by charge, blue stand for positively charged
region and red is negatively charged region; b, Binding pocket detail; c, Major
interactions of the peptide docking.

Docking pose for PRMT1 shows the structure we built from the overlay of
PRMT5 roughly maintains the interactions in the active pocket, which hold by hydrogen
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bonds of E144 and E153 with Arginine on H4, the aromatic rings in TYR152, TYR 148
and TRP 294 surround the pocket area and stable the interactions inside. Outside the
pocket there are D328 and R345 carbonyl group forms hydrogen bonds with Lys8, D187
and D223 forms hydrogen bonds with R19 and K20 respectively. On the PRMT1 surface
negative residue rich area under the β barrel, H4 forms a short helix to make more
attachment with the certain area of the surface.
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2.4.2 MM-PBSA free energy
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Figure 2.4.4 MM-PBSA result for PRMT1; a. table of MM-PBSA estimated free
energy result and experimental K0.5 result; b, MM-PBSA estimated free energy values
are plotted with the orange bar and experimental K0.5 values are plotted with blue dots.
MM-PBSA free energy calculation gives the binding free energy for each modification
on H4 peptide listing below. The binding energy of wildtype H4 with no modifications is
-78.3 kcal/mol, K5ac modification brings the free energy lower to -96.2kcal/mol and
makes the binding more favorable in the simulation, K5me modification indicates even
lower energy of -100.0 kcal/mol and also enhance the binding. S1ph modification
dramatically brings up the binding energy and repress the binding. Compare to the
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biochemical data on each point relatively, the free energy calculation essentially follows
the trend, except for the K5ac.
a.
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b.

d.

c.

e.

Figure 2.4.5 MD trajectories visualization for the peptide binding with PRMT1;
a, superposition of the centroid structure of each largest cluster from the clustering of the
MD trajectories, tan is H4 without modification, blue is the peptide with K5ac
modification, purple is the peptide with K5me modification, green represents the peptide
with S1ph modification; b, the centroid structure of H4 with no modification showing
with sidechain detail and colored with free energy decomposition; c, the centroid
structure of the peptide with K5ac modification showing with sidechain detail and
colored with free energy decomposition; d, the centroid structure of the peptide with
K5me modification showing with sidechain detail and colored with free energy
decomposition; e, the centroid structure of the peptide with S1ph modification showing
with sidechain detail and colored with free energy decomposition.

The centroid structure superposition in figure2.4.5A from the MD trajectory
clustering shows the comparison of the affection of each modification. Some dramatically
change arise out of the modifications. All the structures share the same trend of the tail
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orientation, and the Arg3 is still placed deep inside the active pocket. However, compared
to three peptides with Ser1, the phosphorylate Ser1 brings the N-terminal more away
from the activate site. Also, peptides with no phosphorylation modification share the
short one or two folds α helix around the Gly-rich area on Gly9-Gly12, but
phosphorylated Ser1 brings more shrink turn on the N-terminal area. The Lys5 with
acetylation modification presenting a reversed turn on Gly2 to Gly4, compare with
peptides with non-modified Lys5 or methylated Lys5.
Free energy decomposition for each MD trajectories is coloring on the surface in
the figure2.4.5, and following with the detail interaction visualization. In all the
structures, Arg3 deeply inserted into the active pocket forms strong H bonds with
glutamates on double E loop contributes to the binding with about -9~12kcal/mol free
energy. Lys15, Arg16, Arg18, Lys19 also contribute -3~-8kcal/mol each for the binding
due to the H bond formation with negatively charged residue on the surface of PRMT1
βbarrel. Leu10 contributes via hydrophobic interaction with Val191, Ala192. Ser1
phosphorylation introduced 2 negative charges and formed an inner molecule saltbridge
with Lys5, the balky phosphate group with the saltbridge locate outside the PRMT1
surface and stretch the rest part of peptide outside the position considerably. Methylation
on Lys 5 does not change much on the key interactions, and all the Lys5 are free in the
solvent with fairly little contribution to the binding. However, acetylation reversed the
turn orientation near the binding site because of the negatively charged modification is
pushed away by the negatively charged surface.
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Figure 2.4.6 MM-PBSA result for PRMT5; a. table of MM-PBSA estimated free
energy result and experimental K0.5 result; b, MM-PBSA estimated free energy values
are plotted with the orange bar and experimental K0.5 values are plotted with blue dots.

MM-PBSA binding free energy calculation result for PRMT5 relatively follows
the trend of the biochemical result as far as we have. Both modifications on Lys5 bring
down the binding energy, K5ac binds with -78.0 kcal/mol and K5me binds with 83.0kcal/mol. Phosphorylation on Ser1 considerably increases the binding energy up to 49.9kcal/mol, indicate a less favorable binding with PRMT5.
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Figure 2.4.7 MD trajectories visualization for the peptide binding with PRMT5;
a, the centroid structure of the peptide with K5ac modification showing with sidechain
detail and colored with free energy decomposition; b, the centroid structure of the
peptide with K5me modification showing with sidechain detail and colored with free
energy decomposition; b, the centroid structure of the peptide with S1ph modification
showing with sidechain detail and colored with free energy decomposition.
a.
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b.

c.

Figure 2.4.8 MD trajectories visualization for the peptide binding with PRMT5;
a, superposition of the centroid structure of each largest cluster from the clustering of the
MD trajectories; b, the superposition detail of the Ser1 in different modification states; c,
the superposition detail of the Lys5 in different modification states. For every figure, tan
is H4 without modification, blue is the peptide with S1ph modification, purple is the
peptide with K5ac modification, green represents the peptide with K5me modification;

We visualized the MD trajectories and performed the clustering for each
trajectory, the centroid structure of each largest cluster overlay together for comparison.
As shown in Figure2.4.8, the modifications can not change the binding pose dramatically.
The original binding pose is essentially maintained; each of the peptide backbones
roughly overlaps with others. The figure showing the detail of the binding site reveals the
effects of each modification on the interaction. Three structures with Ser1 are aligned in a
good manner, the hydroxy group face inside of the turn shape, fit in the space held by the
two aromatic groups TYR292 and PHE568. The peptide with phosphorylated Ser1 lays
on a different conformation with the balky phosphate group point outside the pocket to
avoid potential collisions with the nearby aromatic rings. This movement also stretches
the following peptide fragment out of the perfect binding position. The orientation flip
also removes the H-bond on the Ser1 carbonyl group with Gln307.
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2.4.3 Free Energy From Thermodynamic Integration
According to the TIMD calculation, results are listed in the tables and charts in
Figure 2.4.9. For PRMT1, Lys5 methylation increases 5.74kcal/mol of the binding
energy, indicates a lower binding affinity. Lys5 acetylation reduces the binding energy
for 1.07kcal/mol, makes the binding slightly more favorable. Ser1 phosphorylation
dramatically increases the binding energy by 8.83kcal/mol, reduces the binding affinity.
For PRMT5, Lys5 methylation binding energy decreases 5.74kcal/mol, indicates a better
binding affinity. Lys5 acetylation reduces the binding energy for 2.21kcal/mol, makes the
binding more favorable. Ser1 phosphorylation also dramatically increases the binding
energy by 11.31kcal/mol, reduces the binding affinity. The TI calculation result
qualitatively corresponds to the MM-PBSA calculation and follows the trend of the
biochemical results.

57

prmt1
lambda
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
intg.
ΔΔG
(ΔGm-ΔGw)
k0.5

k5me
h4
153.843
48.6785
29.6316
-36.4629
15.5928
34.9333
58.6428
100.809
13.4419
-15.4478
-90.661
28.14102
5.74
0.59

b.

complex
149.584
61.3996
27.8917
25.2722
24.9176
22.0638
24.04
18.4824
10.0108
-14.0541
-101.593
22.40195

k5ac
h4
197.416
139.891
109.801
36.3186
76.3047
89.128
76.5055
29.6926
16.1914
-6.87288
-58.8182
63.62588
-1.07

complex
207.533
143.207
113.444
88.0737
83.3645
51.8031
43.5881
31.5421
19.4211
-2.85427
-56.798
64.69568

0.36

s1ph
h4
19.217
-60.4641
-105.556
-160.074
-186.41
-230.219
-274.463
-330.554
-402.574
-520.369
-816.395
-266.927
8.83

h4
complex
12.1332
-56.801
-105.266
-197.222
-220.185
-264.597
-306.298
-309.56
-383.527
-524.007
-792.429
-275.761
0

5.2

0.45

PRMT1 TIMD

TIMD ΔΔG(ΔGm-ΔGw)
kcal/mol

ΔΔG (ΔGm-ΔGw)

K0.5

10

5.5

8

4.5

6

3.5

4

2.5

2

1.5

0

0.5
k5me

-2

k5ac

s1ph

h4
-0.5

K0.5 μM

a.

58

prmt5

k5me

k5ac

lambda

h4

complex

h4

complex

h4

complex

0.0

144.126

148.515

189.556

197.977

26.4398

14.8188

0.1

65.8956

48.8128

140.575

141.726

-53.2368

-49.8743

0.2

22.7432

29.9195

108.489

116.484

-103.062

-97.6758

0.3

21.3368

-36.5685

81.7724

92.5749

-151.809

-148.778

0.4

23.0619

13.6679

75.5834

72.4016

-181.779

-183.211

0.5

23.4753

36.7468

61.3384

69.9126

-227.666

-216.426

0.6

24.713

60.4507

48.9917

41.1607

-277.524

-256.513

0.7

17.9436

102.505

27.4151

41.7507

-333.506

-311.309

0.8

6.663

7.95566

20.1596

11.2659

-404.509

-392.32

0.9

-31.8885

-12.5158

-6.70636

-9.98875

-529.792

-520.815

1.0

-98.0061

-101.412

-56.4141

-59.8829

-821.968

-755.962

intg.

19.70039

27.45256

62.41892

64.63347

-266.065

-254.749

ΔΔG
(ΔGm-ΔGw)
k0.5

-7.75

-2.21

-11.31

0

0.25

0.3

ND

0.35

d.

s1ph

H4

PRMT5 TIMD
ΔΔG (ΔGm-ΔGw)

K0.5

0

0.4
k5me

-2

k5ac

s1ph

H4
0.35

ΔΔG Kcal/mol

0.3
-4
-6
-8

0.25
0.2
0.15

K0.5 μM

c.

0.1
-10
-12

0.05
0

Figure 2.4.9 TIMD free energy difference estimated results; a, for PRMT1, table
of the average free energy for each windows and the integration of every windows, the
difference of energy for the structure with each modification is highlighted and listed
together with the experimental K0.5 data; b, PRMT1 TIMD free energy difference
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estimated values are plotted with blue bars and experimental K0.5 results are plotted
with orange dots; c, for PRMT5, table of the average free energy for each windows and
the integration of every windows, the difference of energy for the structure with each
modification is highlighted and listed together with the experimental K0.5 data; d,
PRMT5 TIMD free energy difference estimated values are plotted with blue bars and
experimental K0.5 results are plotted with orange dots.
TI trajectories with λ of 0.0 and 1.0 on each structure visualization and H bond
analysis give the major interactions among the binding, in the representation of the
interactions on the residue with no modifications and with modifications by pairwise.
From the analysis, Lys 5 forms H bond with SER25, ASP20, TYR135, TYR139,
respectively. Lys5 with acetylation escape from the surrounding residues and flips to the
other side of the backbone, therefore it loses the previous existing H bonds, then forms a
new H bond with HIS28 sidechain, and some hydrophobic interaction arises with the
additional acetyl group and ILE31. Methylation does not change the original H bonds and
helps to form a new H bond with PRMT1 O-terminal residue ARG340 on the terminal
oxygen. Hydrophobic interaction arises between the new methyl group and TYR139. No
bonding variation with the Ser1 phosphorylation; however, the spatial hindering draws
the bulky phosphate group away from the besiege of the several aromatic rings, together
with the whole peptide, which drags the substrate arginine off the position, dramatically
increases the binding energy. Similar situation observed in the PRMT5 complex, the
difference is an extra H bond formes between the modification phosphate group and
LYS327 on PRMT5, and an inner molecule saltbridge between the phosphate group and
LYS9 arises, leading the LYS9 to a new surrounding and forms an H-bond with TYR302,
helps to counteract the energy increase by a considerable extent. In the PRMT5 complex,
H4K5me presents a similar binding pose with H4, share the same bonding with ASP315.
LYS5 acetylation changes more than methylation, removes the H bond with ASP315.
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Figure 2.4.10 TIMD trajectories with λ=1.0 and 0.0 visualization in detail of the
modification site with the centroid structure of the largest cluster. A. PRMT1 and PRMT5
with H4K5me; B. PRMT1 and PRMT5 with H4K5me; C. PRMT1 and PRMT5 with
H4S1ph;
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2.5

DISCUSSION
From the comparison of modified H4 binding to PRMTs, we can see some major

influence by the modifications on H4. For both PRMT1 and PRMT5, the phosphorylation
on Ser1 brings the bulky phosphate group near the N-terminal as well as the PRMT
substrate Arg3 on the peptide, originally surrounded by several aromatic residues,
whereafter push the N-terminal together with the Arg3 away from the best binding
position to avoid the potential hindering. New H bond forms with the Lys327 or Lys300
sidechain locate on the surface of β barrel and the linker in the PRMT5 situation, whereas
the conserved Lys29 locates further and can not reachable in the PRMT1. Besides, LYS9
tends to forms inner molecule saltbridge with the phosphate group and leave the former
binding anchor. Therefore the slight abscission increases the binding energy in PRMT1 to
a considerable extent, but the new H bond in PRMT5 complex counters the energy
increasing. Modifications on Lys5 of H4 does not affect the backbone location as much
as the phosphorylation because of the better flexibility coming with the longer lysine
sidechain. Methylation on Lys5 leaves the original bonds with PRMT5 and also not form
any new bonds, whereas, in the PRMT1, the methyl group forms new hydrophobic
interaction because of the presence of nearby TYR139 on the double-E loop, which is
more separating by the linker loop within the PRMT5 and makes the conserved PHE438
out of reach. Acetylation on Lys5 pushes the Lysine sidechain away from the negatively
charged area and lose the interact with charged residues, and for PRMT1, ILE31 forms
new interaction with the hydrophobic effect which counters the energy increase.
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2.6

CONCLUSIONS
The docking for the PRMT-H4 binding complex gives reasonable docking poses

for PRMT1 and PRMT5. Then MD simulation trajectories comparison and free energy
calculation results indicate the binding energy change with the modification, and we can
identify some key interactions in dominance. Spacial hindering and the inner molecule
saltbridge are the adverseness brought by the phosphorylation on Ser1 and bring up the
binding energy in both cases. Lys5 modifications affect less on the perspective of energy
compares to the Ser1 phosphorylation. The methylation creates a hydrophobic end and
slightly adds on the positive charge of Lysine. Therefore Lys5 with methylation tends to
keep the original bonding with PRMTs, and interacts with the hydrophobic area nearby in
the case of PRMT1. Acetylation on Lys5 removes the positive charge from the sidechain
amino group and also creates a hydrophobic end, which removes the electrostatic
interactions with the negative surface area, hydrophobic interactions replace electrostatic
interactions as contributing to the binding. Overall, the energy estimation by TI and MMPBSA essentially follows the trend of the biochemical experimental data variation
qualitatively, the analysis on the trajectories revealed the key interactions in the binding
and how the modifications affect on each binding site, and further influence the binding
energy. These studies together with further experimental results will help to reveal the
H4-substrated PRMT regulation mechanisms.
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